CA-LIVERAMP
8.2.2021 22:03:07 CET | Business Wire | Press release
LiveRamp ® (NYSE: RAMP), the leading data connectivity platform, today announced that it has entered into a definitive agreement to acquire DataFleets , a cloud data platform that enables data silos to be unified without moving data or compromising privacy. This acquisition expands LiveRamp’s data protection capabilities to unlock greater data access and control for its customers. In addition, the deal opens up new use cases as well as new markets for distributed data collaboration through LiveRamp Safe Haven.
With the exponential growth of data, enterprises are constantly evaluating how to best access and leverage data to fuel growth and innovation. Regardless of size, sector or geography, every company is trying to build a data strategy for competitive advantage. However, heightened privacy regulations and security considerations often put limitations on how data can be used or analyzed. Leveraging multiple advanced mathematical privacy technologies, DataFleets offers products that unify distributed data for collaboration and analytics without moving raw data beyond an enterprise’s firewall. Some early and existing privacy tools suffer from a limited set of operations and capabilities that they can handle safely. Now with DataFleets technology, enterprises can access a modern, rich set of data protection tools that can be configured based on each business’s needs. DataFleets’ federated learning technology makes it possible to analyze data across borders and silos in fragmented architectures, as if they were all aggregated to one location. Simply put, DataFleets keeps private data useful, and useful data private.
“This transformative acquisition combines LiveRamp’s deep privacy expertise and widely adopted platform with DataFleets’ game-changing technology, unlocking massive value for the entire ecosystem,” said Anneka Gupta, president and head of products and platforms at LiveRamp. “Together, our combined capabilities will pave the way for the next generation of privacy technology, serving as the foundation for our platform and products, and underscoring our commitment to making it safe and easy for enterprises to use data – wherever it lives.”
With the addition of DataFleets, LiveRamp will further extend its ability to meet evolving marketplace demands by strengthening its differentiated capabilities across four foundational pillars:
- Unlocking Data Access —Proprietary data is available for analytics without requiring the movement of data
- Privacy-Preserving Technology —Identity resolution and collaboration workflows across distributed data sets are supported without compromising privacy or security
- Extended, Global Connectivity —Deeper connections are enabled across data sets formerly siloed by infrastructures, industries and geographies
- Total Control —LiveRamp customers keep continuous control over their data while collaborating and have the ability to choose the right approach and level of data protection to meet their business needs
DataFleets provides Safe Haven customers more flexible options for distributed data collaboration, as well as unlocks privacy-protecting analytics use cases for new industries such as healthcare and financial services. In addition, DataFleets helps LiveRamp’s products and solutions adapt across jurisdictions with privacy designed into their infrastructure layers, empowering customers to comply with evolving privacy regulations around the world.
“With the addition of DataFleets’ technology and their deeply experienced team of industry experts, LiveRamp is now even better positioned to expand our capabilities across geographies and industries,” said Warren Jenson, president and chief financial officer, LiveRamp. “This transaction will support the expansion of LiveRamp’s offerings throughout Europe and in Asia-Pacific and the Latin American market in 2021, and help propel us into new addressable industries like healthcare and financial services, where the combination of DataFleets and LiveRamp together will power high-value use cases.”
David Gilmore, CEO of DataFleets, added, “We are incredibly excited to join the LiveRamp team and continue executing on our shared vision of helping enterprises unify data to unlock maximum value, all while upholding consumer privacy and control. The synergies are strong, and together we can help global enterprises remove barriers to data access and usage to power insights and innovation across their businesses.”
To learn more about LiveRamp’s acquisition of DataFleets, please visit: https://liveramp.com/blog/liveramp-to-acquire-datafleets .
Financial Impact and Closing
The transaction is expected to be completed in LiveRamp’s fiscal fourth quarter. The transaction is not expected to have a material impact on LiveRamp’s fiscal 2021 financial results.
The addition of DataFleets extends LiveRamp’s lead in privacy-preserving identity and data collaboration, driving continued strong growth and value for LiveRamp shareholders.
Third Quarter 2021 Earnings Results
In a separate press release issued today, the Company announced its earnings results for the third quarter of 2021. LiveRamp will host a conference call today at 1:30 pm P.T. to discuss the transaction, as well as its fiscal third quarter 2021 earnings results.
About LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005758/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom